Transparency Market Research (TMR) has recently published a research study on the global peptide therapeutics market . According to this report, the market is estimated to expand at a moderate CAGR of 2.80% during the period from 2014 to 2020 and reach a value of US$23.7 bn by the end of the forecast period.The research study, titled “Peptide Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020,” states that the worldwide peptide therapeutics market stood at US$18.9 bn. The rising prevalence of cancer and other diseases is identified as the key factor behind the growth of this market in this research study.
Therapeutic peptides are naturally occurring short amino acid monomer chains, which are beneficial in the treatment of several kinds of cancer, respiratory disorders, cardiovascular disorders, central nervous system (CNS) disorders, blood-related disorders, and other chronic diseases. More than seven thousand organically occurring peptides have been identified till now. Insulin was the first peptide, to be therapeutically administered. Although being used for more than 50 years now, it still enjoys the reputation of the most commonly prescribed peptide.
The research report has studied the global peptide therapeutics market on the basis of application, the route of administration, marketing status, and its regional spread. Based on application, the market is classified into cancer, central nervous system disorders, cardiovascular disorders, gastrointestinal disorders, hematological disorders, respiratory disorders, infections, and acromegaly.
By the route of administration, the report has segmented the peptide therapeutics market into oral administration and parenteral administration and by marketing status, the market has been categorized as branded therapeutic peptides and generic therapeutic peptides.
On the regional front, the worldwide peptide therapeutics market has been classified into Europe, Asia Pacific, North America, and the Rest of the World. In 2014, North America and Europe collectively occupied a share of more than 60% in the overall market.
Asia Pacific, on the other hand, is emerging as the most promising market for peptide therapeutics across the world. Over the forecast period, analysts project Asia Pacific to register the fastest growth among all the regional markets for peptide therapeutics, states the research report.
Japan, China, and India lead the Asia Pacific peptide therapeutics market on account of large pool of patients suffering from cancer and other chronic ailments in these countries. The rapid development in economic condition and the rising awareness pertaining to the treatment of cancer and various other chronic diseases, using therapeutic peptides, are the other prominent factors anticipated to boost the peptide therapeutics market in Asia Pacific, notes the study.
Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Sanofi, Roche Holdings AG, PolyPeptide Group, Novo Nordisk A/S, Novartis AG, Merck & Co. Inc., Lonza Group Ltd., Ipsen S.A., Eli Lilly and Co., CordenPharma International GmbH, Bachem Holding AG, AstraZeneca Plc, and Amgen Inc. are some of the major companies operating in the global peptide therapeutics market, profiled in this report.
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.